CASI Pharmaceuticals Inc (CASI)

CASI Pharmaceuticals Inc Borsa (CASI) Ultime notizie

HC Wainwright Lowers CASI Pharmaceuticals (NASDAQ:CASI) Price Target to $6.00 - Defense World

Defense World

CASI Pharmaceuticals, Inc. Expected to Post FY2028 Earnings of ($1.36) Per Share (NASDAQ:CASI) - Defense World

Defense World

CASI Pharmaceuticals shares target cut by H.C.Waingwright on increased competition - Investing.com South Africa

Investing.com South Africa

FDA clears CASI's new drug application for ITP treatment - Investing.com India

Investing.com India

Casi Pharma stock spikes on FDA nod for study (NASDAQ:CASI) - Seeking Alpha

Seeking Alpha

CASI Pharmaceuticals shares target cut by H.C.Waingwright on increased competition - Investing.com UK

Investing.com UK

CASI Pharmaceuticals Receives FDA Clearance On The Investigational New Drug (IND) Application For CID-103 In ... - PR Newswire

PR Newswire

CASI Pharmaceuticals (NASDAQ:CASI) Receives New Coverage from Analysts at StockNews.com - Defense World

Defense World

CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2024 BUSINESS AND FINANCIAL RESULTS - PR Newswire

PR Newswire

CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2024 BUSINESS AND FINANCIAL RESULTS ... - Financial Times

Financial Times

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Sees Significant Drop in Short Interest - Defense World

Defense World

CASI Pharmaceuticals (NASDAQ:CASI) Coverage Initiated by Analysts at StockNews.com - Defense World

Defense World

CASI Pharmaceuticals (NASDAQ:CASI) Coverage Initiated by Analysts at StockNews.com - Defense World

Defense World

Even after rising 58% this past week, CASI Pharmaceuticals (NASDAQ:CASI) shareholders are still down 88% over the ... - Yahoo Movies Canada

Yahoo Movies Canada

Even after rising 58% this past week, CASI Pharmaceuticals (NASDAQ:CASI) shareholders are still down 88% over the ... - Yahoo Movies Canada

Yahoo Movies Canada

Analysts Are Optimistic We'll See A Profit From CASI Pharmaceuticals, Inc. (NASDAQ:CASI) - Yahoo Finance

Yahoo Finance

Head to Head Contrast: CASI Pharmaceuticals (NASDAQ:CASI) versus Oramed Pharmaceuticals (NASDAQ:ORMP) - Defense World

Defense World

CASI Pharmaceuticals updates on Juventas dispute By Investing.com - Investing.com

Investing.com

CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL ... - PR Newswire

PR Newswire

Investors Don't See Light At End Of CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Tunnel And Push Stock Down 26% - Simply Wall St

Simply Wall St

Breakeven Is Near for CASI Pharmaceuticals, Inc. (NASDAQ:CASI) - Simply Wall St

Simply Wall St

CASI Stock Quote Price and Forecast - CNN

CNN

CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory ... - PR Newswire

PR Newswire

CASI begins dosing lymphoma patients with pralatrexate in China - Clinical Trials Arena

Clinical Trials Arena

Top 5 NASDAQ Pharma Stocks of 2023 - Investing News Network

Investing News Network

CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2023 BUSINESS AND FINANCIAL UPDATES - PR Newswire

PR Newswire

CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATES - PR Newswire

PR Newswire

CASI Acquires Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339 - Contract Pharma

Contract Pharma

Cleave Therapeutics Announces Acquisition of Clinical and Preclinical Assets - Business Wire

Business Wire

CASI PHARMACEUTICALS COMPLETES REDOMICILIATION MERGER - PR Newswire

PR Newswire

A CASI Pharmaceuticals, Inc. (NASDAQ:CASI) insider increased their holdings by 16% last year - Yahoo Canada Shine On

Yahoo Canada Shine On

CASI PHARMACEUTICALS AND CLEAVE THERAPEUTICS ANNOUNCE CLINICAL TRIAL APPLICATION APPROVAL ... - PR Newswire

PR Newswire

CASI PHARMACEUTICALS' PARTNER JUVENTAS ANNOUNCES NEW DRUG APPLICATION FOR CNCT19 ... - PR Newswire

PR Newswire

James Huang Net Worth (2024) - GuruFocus.com

GuruFocus.com

CASI PHARMACEUTICALS ANNOUNCES EXIT OF JUVENTAS INVESTMENT TO STRENGTHEN BALANCE SHEET - PR Newswire

PR Newswire

CASI PHARMACEUTICALS ANNOUNCES ITS PARTNER, PRECISION AUTOIMMUNE THERAPEUTICS CO., LTD ... - PR Newswire

PR Newswire

CASI PHARMACEUTICALS ANNOUNCES REVERSE STOCK SPLIT - PR Newswire

PR Newswire

CASI PHARMACEUTICALS ENTERS INTO SUBLICENSE AGREEMENT WITH TIANSHI PHARMACEUTICALS FOR ... - PR Newswire

PR Newswire

CASI PHARMACEUTICALS ANNOUNCES RENEWAL OF EXCLUSIVE DISTRIBUTION AGREEMENT FOR EVOMELA ... - PR Newswire

PR Newswire

CASI Pharmaceuticals(NASDAQ: CASI) Partner BioInvent International AB receives ODD for BI-1206 in FL - BP Journal

BP Journal

CASI PHARMACEUTICALS ANNOUNCES CNCT19 (CD19 CAR-T) GRANTED ORPHAN DRUG DESIGNATION BY ... - PR Newswire

PR Newswire

4 Penny Stocks Insiders Are Buying - Yahoo Finance

Yahoo Finance

CASI Pharmaceuticals Announces Pricing Of $32,500,000 Public Offering Of Common Stock - PR Newswire

PR Newswire

Cleave Therapeutics Licenses First-in-Class VCP/P97 Inhibitor CB-5339 To CASI Pharmaceuticals For Greater China ... - PR Newswire

PR Newswire

BioInvent licenses anti-FcγRllB antibody BI-1206 to CASI Pharmaceuticals for Greater China region - PR Newswire

PR Newswire

CASI Pharmaceuticals Announces Restructuring of Partnership with Juventas Cell Therapy Ltd - PR Newswire

PR Newswire

CASI Pharmaceuticals Announces Full Year 2019 Financial Results - BioSpace

BioSpace

CASI Pharmaceuticals Acquires Worldwide Rights To Commercialize anti-CD19 T-cell Therapy - PR Newswire

PR Newswire

CASI Pharmaceuticals In-Licenses Exclusive Worldwide Rights to Novel Anti-CD38 Monoclonal Antibody Program ... - PR Newswire

PR Newswire

CASI Pharmaceuticals Acquires ANDA Portfolio From Sandoz Inc. (Sandoz) - PR Newswire

PR Newswire